Table 2. Univariate and multivariate analyses of different prognostic parameters in 128 patients with NSCLCs.
| Univariate analysis | Multivariate analysisa | Multivariate analysisb | Multivariate analysisc | |||||
|---|---|---|---|---|---|---|---|---|
|
Variables |
HR (95% CI) |
P-value |
HR (95% CI) |
P-value |
HR (95% CI) |
P-value |
HR (95% CI) |
P-value |
|
Sex | ||||||||
| Male | 1.000 | |||||||
| Female |
0.990 (0.650–1.510) |
0.964 |
|
|
|
|
|
|
|
Age, years | ||||||||
| ≦60 | 1.000 | |||||||
| >60 |
0.831(0.555–1.243) |
0.367 |
|
|
|
|
|
|
|
Smoking status | ||||||||
| No | 1.000 | |||||||
| Yes |
0.945 (0.633–1.411) |
0.782 |
|
|
|
|
|
|
|
CEAd | ||||||||
| − | 1.000 | |||||||
|
+ |
0.951 (0.613–1.477) |
0.824 |
|
|
|
|
|
|
|
NSEe | ||||||||
| − | 1.000 | |||||||
|
+ |
1.267 (0.750–2.139) |
0.377 |
|
|
|
|
|
|
|
EGFRf | ||||||||
| − | 1.000 | |||||||
|
+ |
0.833 (0.420–1.650) |
0.600 |
|
|
|
|
|
|
|
Histology | ||||||||
| Adenocarcinoma | 1.000 | |||||||
| Squamous carcinoma |
0.747 (0.476–1.173) |
0.205 |
|
|
|
|
|
|
|
Differentiation | ||||||||
| Well–moderate | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Poor |
1.511 (1.009–2.261) |
0.045 |
1.455 (0.943–2.245) |
0. 090 |
1.068 (0.680–1.676) |
0.776 |
1.093 (0.705–1.693) |
0.691 |
|
T stage | ||||||||
| T1 | 1.000 | |||||||
| T2 | 1.067 (0.652–1.747) | 0.795 | ||||||
| T3–T4 |
1.130 (0.819–1.559) |
0.456 |
|
|
|
|
|
|
|
N stage | ||||||||
| N0 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| N1–N3 |
2.212 (1.473–3.320) |
<0.001 |
1.516 (0.938–2.448) |
0.089 |
1.494 (0.923–2.419) |
0.102 |
1.480 (0.908–2.412) |
0.116 |
|
M stage | ||||||||
| M0 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| M1 |
4.855 (2.928–8.051) |
<0.001 |
2.099 (1.162–3.793) |
0.014 |
1.832 (1.026–3.272) |
0.041 |
1.892 (1.054–3.399) |
0.033 |
|
Clinical stage | ||||||||
| I–II | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| III–IV |
3.468 (2.283–5.269) |
<0.001 |
2.709 (1.630–4.502) |
<0.001 |
2.668 (1.591–4.473) |
<0.001 |
2.690 (1.617–4.474) |
<0.001 |
|
Pyk2 expression | ||||||||
| Lowg | 1.000 | 1.000 | 1.000 | |||||
| Highg |
2.423 (1.594–3.685) |
<0.001 |
2.089 (1.346–3.241) |
0.001 |
|
|
1.480 (0.908–2.412) |
0.116 |
|
Pyk2[pY881] expression | ||||||||
| Lowh | 1.000 | 1.000 | 1.000 | |||||
| Highh | 3.505 (2.231–5.505) | <0.001 | 3.086 (1.941–4.907) | <0.001 | 3.223 (2.017–5.150) | <0.001 | ||
Abbreviations: CEA=carcinoembryonic antigen; CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio; NSCLC=non-small-cell lung cancer; NSE=neuron-specific enolase; Pyk2=proline-rich tyrosine kinase 2. Bold values indicates statistical significance.
a
Pyk2[pY881] excluded.
b
Pyk2 excluded.
c
Pyk2 and Pyk2[pY881] included.
d
CEA: −, normal (0–5 ng ml−1); +, elevated (>5 ng ml−1); 18 patients' CEA unknown.
e
NSE: −, normal (0–15.2 ng ml−1); +, elevated (>15.2 ng ml−1); 41 patients' NSE unknown.
f
EGFR: −, no EGFR mutation and amplification; +, EGFR mutation or amplification; 77 patients' EGFR unknown.
g
Pyk2 low expression: score ⩽3; high expression: score ⩾4.
h
Pyk2[pY881] low expression: score ⩽3; high expression: score ⩾4.